Introduction
The phosphatidylinositol-3-OH kinase/Akt/mammalian target of rapamycin (mTOR) pathway regulates various cellular processes, including proliferation, growth, survival and mobility. The pathway is commonly deregulated in cancer (Morgensztern and McLeod, 2005; Shaw and Cantley, 2006) , and clinical trials, including trials at the Phase III stage for breast cancer, are currently underway to test the efficacy of treatment using mTOR antagonists. Although preclinical and early clinical results have been encouraging, there is a real need for biomarkers for selecting those patients who may benefit most from anti-mTOR therapy (Morgensztern and McLeod, 2005; Johnston, 2006) . Recent studies have defined mRNA expression patterns, or 'signatures', of deregulation of specific pathways -including Myc, Ras, cyclin D1, b-catenin, HER2/neu, epidermal growth factor receptor and mitogen-activated protein kinasein human cancer (Lamb et al., 2003; Sweet-Cordero et al., 2005; Bild et al., 2006; Creighton et al., 2006a, b) . Preclinical studies indicate that these oncogenic signatures could be used as a guide for targeted therapies (Bild et al., 2006) . To date, no mRNA signature has been defined for the Akt pathway in human breast cancer. A recent study by Majumder et al. (2004) carried out global gene expression profiling of a transgenic mouse model of Akt activation, although the observed expression patterns were not examined in clinical tumor specimens. This study describes a meta-analysis combining Majumder's data with five independent expression profile data sets of human breast tumors (van de Vijver et al., 2002; Sorlie et al., 2003; Ma et al., 2004; Miller et al., 2005; Wang et al., 2005) , with the goal of determining whether a gene signature of Akt in human breast cancer can be defined and in which tumor subtypes the pathway appears to be deregulated.
Results

A gene expression signature of Akt overexpression in a transgenic mouse model
In the study by Majumder et al. (2004) , a probasin promoter-myr-HA-AKT1 transgene was used to direct production of activated Akt1 spatially restricted to the luminal epithelial cells of the mouse ventral prostrate (AKT1-Tg). The AKT1-Tg mice developed a highly penetrant prostatic intraepithelial neoplasia (PIN) phenotype. This PIN phenotype was completely dependent on mTOR activation, as treatment with mTOR inhibitor RAD001 induced apoptosis and reversed the PIN phenotype within 2 weeks. To identify genes altered by Akt expression and by subsequent mTOR inhibition, Majumder et al. (2004) prepared total RNA after 12 or 48 h of RAD001 or placebo treatment in wild-type and AKT1-Tg mouse prostate, and message abundance was determined for over 20 000 genes using microarrays. From this expression profile data set, it was determined that gene targets of mTOR inhibition were enriched for Hif-1 targets and glycolysis genes (Majumder et al., 2004) .
In this study, the Majumder profile data were reanalysed in the context of clinical breast cancer. A gene expression signature of activated Akt was first defined, as shown in Figure 1 . The mouse genes represented in the profile data set were mapped to their human orthologs, representing 11 120 unique named genes in all. When comparing placebo-treated AKT1-Tg prostate to placebo-treated wild-type prostate, 2839 unique genes were found differentially expressed (Po0.01), 1377 of these genes being overexpressed in AKT1-Tg, and 1519 being under-expressed (67 genes represented in the overexpressed group were also represented in the under-expressed group by different microarray probes). Putative targets of the mTOR branch of the Akt pathway -genes affected by RAD001 treatment -were determined by comparing the RAD001-treated and placebo-treated AKT1-Tg groups. Of the 1377 Aktinduced genes, 419 showed downregulation (Po0.05) by RAD001 (the patterns of downregulation being more evident in the 48 h-over the 12 h-treated samples, see Figure 1 ); of the 1519 Akt-repressed genes, 404 showed upregulation by RAD001.
The mouse model Akt signature genes are coordinately expressed with AKT1 in human breast tumors The above gene expression signature of Akt activation (Figure 1 ) was derived from a mouse model of Akt overexpression in prostate. An important question was whether these genes were model-or tissue-specific or whether they could apply to human breast cancer. To answer this, enrichment analysis was carried out to determine whether any association existed between the AKT1-Tg signature genes and Akt-associated expression patterns in human breast tumor data sets. Enrichment in this context was defined as a significant number of a set of experimentally generated genes (e.g., the genes induced in AKT1-Tg over wild-type prostate) being located at or near the top of the population of genes in the human tumor data set ranked by similarity (i.e. correlation) to AKT1 mRNA. The genes at the top of the human tumor ranked list would be most similar to AKT1, and the gene at the bottom, least similar. A schematic of enrichment is shown in Figure 2a . In tissuebased studies (e.g. references Bose et al., 2006; Tokunaga et al., 2006) , Akt is often measured in its phosphorylated form, whereas here AKT1 mRNA was used as a surrogate for p-Akt. By Q1-Q2 enrichment analysis method (Tian et al., 2005) (results shown in Figure 2b ), the set of genes induced in AKT1-Tg were co-expressed as a group with AKT1 mRNA in human breast tumors. In other words, tumors with high levels of Akt also had high expression of a significant number of genes in the AKT1-Tg set. This association was found to be significant in each of the five independent tumor data sets (Po1 Â 10E-06 van de Vijver, Wang, Miller, Sorlie data sets; Po0.002 Ma data set) and can be considered quite robust, as the significance values indicate enrichment over any randomly assigned genes to the AKT1-Tg set or any random assortment of AKT1 mRNA values within the breast tumor data sets. The subsets of the AKT1-Tginduced genes that were RAD001-sensitive or -insensitive each showed significant enrichment as well (Figure 2b ). The set of genes downregulated in AKT1-Tg were also examined for anti-enrichment with respect to AKT1 in breast cancer, but no such patterns were consistently observed (Figure 2b) .
The Akt-associated human tumor enrichment patterns described above were evident when viewing the gene expression patterns involved using a color map representation (Figure 2c ). In the three breast tumor profile data sets with the most samples (van de Vijver, Wang and Miller) , the subset of tumor profiles with very high or very low AKT1 mRNA levels (71 s.d. from mean) were examined. AKT1 mRNA levels did not correlate with estrogen receptor (ER) or progesterone receptor (PR) mRNA in breast tumors (Figure 2c ), although tumors with high AKT1 did tend to have high levels of HER2 mRNA (Po0.05 all three data sets). Of the 1144 genes induced in AKT1-Tg that were represented in at least two of the three tumor data sets, 272 (101 of these being RAD001-sensitive) were higher (Po0.05 in at least two data sets) in breast tumors having high AKT1, where the expected chance overlap was 147 (enrichment Po1 Â 10E-25, one-sided Fisher's exact); only 72 were lower, which was around the chance expected (78, enrichment P ¼ 0.78). Table 1 lists the top 57 AKT1-Tg-induced genes best correlated with AKT1 in tumors (Po0.01 all three data sets, comparing high AKT1 to low AKT1 tumors).
The Akt-mTOR signature genes predict poor prognosis in multiple breast cancer patient cohorts Previous studies have associated activation of the Akt-mTOR pathway in breast tumors with poor patient outcome (Bose et al., 2006; Tokunaga et al., 2006) . In this study, the gene signatures of Akt-mTORdependent (RAD001-sensitive) and Akt-mTOR-independent (RAD001-insensitive) pathways were each examined for correlation to patient outcome. As only the genes upregulated by Akt in AKT1-Tg mice and not For a given breast tumor profile data set, genes represented are first ranked by similarity (i.e. correlation) with AKT1 mRNA. For a given set of genes derived from the Akt signature of Figure 1 , the locations of the genes are plotted along the human tumor rank-ordered list. Enrichment is defined as a significant number of genes in the experimental set being located at or near the top of the rank-ordered list. (b) Enrichment analysis results across five different profile data sets of human breast tumors. Akt gene sets tested for enrichment included the genes upregulated and the genes downregulated by Akt (the subsets of RAD001-sensitive and -insensitive genes being tested as well). Red, enrichment; blue, anti-enrichment. (c) Expression patterns across AKT1-Tg model and three human tumor data sets for the genes induced (Po0.01) in AKT1-Tg (genes not represented in at least two tumor data sets not shown; gray, gene not represented). For the human tumor data sets, the subset of tumor profiles with very high or very low AKT1 mRNA levels (71 s.d. from mean) are shown. The order of the genes is the same for each of the data sets represented. RNA levels for Akt, ER, PR and HER2 are also shown.
the downregulated genes showed significant patterns in the human tumors (Figure 2b ), the downregulated genes were not considered here. In the van de Vijver, Miller and Sorlie tumor profile data sets, it could be observed that tumors with high average expression of the Akt-induced, RAD001-sensitive genes tended to have more cases of metastases as compared with the rest of the tumors (Figure 3a) . For the van de Vijver, Miller and Sorlie patient cohorts, Kaplan-Meier analysis (Figure 3b) showed that the top 30% of tumors with Across the human tumors, the average expression of the Akt-induced, RAD001-insensitive genes was correlated with that of the RAD001-sensitive genes (Figure 3a) . Interestingly, however, the RAD001-insensitive genes as a group did not show any correlation with survival by Kaplan-Meier in the van de Vijver or Miller cohorts but were correlated with poor outcome in the Sorlie cohort (P ¼ 0.01, Figure 3c ). As shown above (Figure 2 ), AKT1 mRNA was correlated with the average expression of the Akt, RAD001-sensitive genes, although the correlation was not perfect, some tumors with high AKT1 mRNA did not express the AKT1 signature genes, whereas other tumors with low AKT1 did (Figure 3a) . Furthermore, AKT1 mRNA alone was not predictive of outcome (Figure 3d) .
The Kaplan-Meier analysis required that a decision be made for the cutoff point between high-risk and low-risk groups for comparison (previous studies indicated that on the order of 30% of breast tumors have Akt pathway deregulation (Bose et al., 2006; Tokunaga et al., 2006) ). In addition to Kaplan-Meier, the average expression of the Akt, RAD001-sensitive genes was treated as a continuous variable by univariate Cox regression analysis. In the van de Vijver, Miller and Sorlie data sets, increasing average values were significantly associated with poor outcome (P ¼ 0.0008, P ¼ 0.001 and P ¼ 0.0001, respectively); this association was not observed in the Wang (P ¼ 0.52) and Ma (P ¼ 0.11) data sets. The Akt, RAD001-insensitive genes were significant by Cox in the Sorlie data set (P ¼ 0.002), and interestingly, these genes were also significant in the the Miller data set (P ¼ 0.001) and marginally significant (P ¼ 0.05) in the van de Vijver data set, although the correlation Figure 3 The Akt-mTOR signature genes predict poor prognosis in multiple breast cancer patient cohorts. (a) For each of five breast tumor data sets, the average expression (yellow: high; blue: low) for the set of genes induced in AKT1-Tg and sensitive to RAD001 (Figure 1 ) and the set of genes induced in AKT1-Tg and insensitive to RAD001 are shown. Also shown is the corresponding expression patterns of AKT1 mRNA, as well as ER status and whether the patient developed metastases. (b) Kaplan-Meier analysis across the five data sets comparing the differences in risk between patients having high average expression (top 30% of patients) of the Akt-induced, RAD001-sensitive genes and patients with low average expression (bottom 70%). P-values by log-rank statistic, (c) as in (b), but for the Akt-induced, RAD001-insensitive genes, (d) as in (b) and (c), but for AKT1 mRNA.
with outcome for these data sets was not as strong as for the Akt, RAD001-sensitive genes. AKT1 mRNA itself was not significantly associated with survival by Cox.
To determine whether the above correlations with patient outcome of the Akt-induced, RAD001-sensitive genes could have arisen in a chance set of genes, a simulation test was carried out using the van de Vijver data set. For each of 1000 randomly generated gene sets, the average expression was calculated and the correlation of this average with survival determined by Cox. In only one of the 1000 tests was the simulated Cox P-value lower than the actual P-value. When the same type of simulation was carried out for the Akt, RAD001-insensitive genes, 28% of the random gene sets yielded P-values lower than the actual P-value of 0.05, indicating that it may only be nominally significant. For the van de Vijver, Miller and Sorlie data sets, the subset of ER-positive tumors were also examined for survival correlations: the Akt, RAD001-sensitive genes were prognostic in all three data sets (Po0.05 by Cox), whereas the Akt, RAD001-insensitive genes were prognostic only in the Sorlie data set (P ¼ 0.01).
Association of the Akt-mTOR signature genes with ER-status, tumor grade and tumor size In each of the five above-mentioned breast tumor expression profile data sets, an examination was made for correlations between the AKT1-Tg signature genes and various tumor characteristics (Table 2) . For ER-, PR-and HER2 status, mRNA expression as measured by microarrays was used as the surrogate for protein expression, as there is high correlation between RNA and protein for these genes (van de Vijver et al., 2002; Paik et al., 2004; Ma et al., 2006) . For the set of Akt-induced, RAD001-sensitive (i.e. mTOR-dependent) genes, the average expression was significantly anticorrelated (Po0.01) with ER expression in each of the five data sets. From Figure 3a , it could be observed that tumors with high average expression of the Akt-induced, RAD001-sensitive genes tended to have ER-negative status. In three of the five data sets examined, the average of the Akt-induced, RAD001-insensitive (i.e. mTOR-independent) genes were also significantly anticorrelated with ER; AKT1 itself was anti-correlated with ER in two of five data sets. No consistent correlation patterns were observed between the Akt-associated genes and PR expression. In three of the data sets, the Akt, RAD001-sensitive genes were positively correlated (Po0.05) with HER2, but anti-correlated in a fourth data set.
In three of four tumor profile data sets for which tumor grade information was available, the Akt, RAD001-sensitive genes were positively correlated (Po0.005) with increasing grade. In each of the three data sets for which tumor size information was available, AKT1 mRNA and the Akt signature gene sets (both RAD001-sensitive and -insensitive) were all highly correlated with increasing size, with this trend being most significant for the RAD001-sensitive gene set. No consistent correlations were observed between the Akt signature genes and lymph node status.
Discussion
Molecular data from experimental models represent dynamic information, where genes can be manipulated and the effects observed, although the clinical relevance of such models may not initially be clear. In contrast, data from clinical tumor specimens represent more static information, where the associations observed may be pathologically relevant, but where cause-and-effect associations cannot be distinguished from mere correlation. In this context, the link made in this study between a transcriptional signature of Akt derived from transgenic mouse models and Akt expression patterns in breast tumors is important. The set of genes associated here with the Akt pathway in both the functional and clinical data sets represent excellent candidates for further study. Furthermore, many tumor specimens having low Akt expression had the Akt gene signature; these tumors could perhaps have had the Akt pathway deregulated through some means other than AKT1 overexpression (e.g., mTOR or S6K hyperactivation). In this way, the Akt gene signature could possibly be used as a better indicator of pathway dysfunction in tumors than Akt alone. Although the focus of this study was on breast cancer, it is anticipated that the Akt-mTOR signature could be applied in a similar manner to other cancers. Genes activated by the mTOR branch of the Akt pathway were associated with increasing tumor grade and size, loss of ER expression and poor clinical outcome, whereas these associations were weaker or not present for the mTORindependent genes in the Akt pathway. These findings indicate that mTOR is an essential therapeutic target of the Akt pathway. It is notable that Akt has been previously thought to be involved in development of resistance to hormone therapy (Kirkegaard et al., 2005; Tokunaga et al., 2006) . The association of the Akt-mTOR genes with poor prognosis was found in some but not all patient data sets examined, although it is not readily apparent that this reflects the different treatment regimens being represented among the various tumor profiling studies. None of the represented patients likely received anti-mTOR therapy.
Ultimately, the utility of a definition of an AktmTOR gene signature in human cancer will not be in its prognostic ability but in its therapeutic predictive ability. It is understood that some but not all of breast cancers have deregulated mTOR pathway, and it is reasonable to postulate that the patients that do would best respond to therapies targeting mTOR. The challenge of developing a molecular diagnostic of AktmTOR deregulation is that there are so many pathway intermediates at the signal transduction level that one must consider. The pathway can be deregulated through any one of a number of ways, not all of which may be known. This study suggests that all of these deregulatory mechanisms lead to transcriptional activation of a core set of genes. Reverse transcription-polymerase chain reaction (RT-PCR) assays using RNA from paraffin-embedded tissues have recently been developed (Lehmann and Kreipe, 2001; Paik et al., 2004) , and so it is technically feasible to develop an RT-PCR assay of Akt-mTOR activation. Such an assay could first be tested retrospectively for prognostic ability in breast cancer patients treated with anti-mTOR therapy, as tissue specimens become available. It is hoped that this study could help lead eventually to our being able to predict prospectively which patients should receive mTOR antagonist treatment, much in the same way that we now predict response to hormone therapy or anti-HER2 therapy using ER or HER2.
Materials and methods
The gene expression profile data sets described here were publicly available (van de Vijver et al., 2002; Sorlie et al., 2003; Ma et al., 2004; Majumder et al., 2004; Miller et al., 2005; Wang et al., 2005) . From the Ma et al. (2004) study, the 'whole tumor' data set was used (GEO accession number GSE1379). For the Miller et al. (2005) data set, only the U133A probe set was analysed. For reasons not related to this study, the four profiles from the original Miller data set for which ER status was not given were removed from the analyses. For the Sorlie et al. (2003) data set, gene probes with poor quality data in at least half of the ER þ tumor specimens were removed from consideration. Gene expression values were log-transformed and normalized to s.d. from the mean. The Entrez Gene identifier was used in mapping genes across the tumor data sets; where a gene was represented multiple times on a given platform, the probe with the greatest variation was used.
Two-sample t-tests determined significant differences in gene expression between groups of samples. Expression values were visualized as heat maps using the Cluster (Eisen et al., 1998) and Java TreeView software (Saldanha, 2004) . Correlations between patient outcome and gene expression were measured by Cox proportional hazards regression model (using the 'survival' library of the R software package, www.r-project. org); P-values given were two-sided. Kaplan-Meier analysis was carried out using WinSTAT (www.winstat.com). For Q1-Q2 analysis (see below), custom software was developed using Excel VBA.
In order to determine whether a specified group of genes (e.g. genes induced in AKT1-Tg mouse model) had a coordinated association with a molecular phenotype of interest (e.g. breast tumors with high AKT expression), Q1-Q2 analysis was carried out essentially as described by Tian et al. (2005) . Briefly, the common population of genes represented in the given human breast tumor profile data set were ranked based on Pearson's correlation with AKT1 mRNA. For genes in the given experimental set of interest, the t-scores for the correlation coefficients in the tumor data set were summed up; the significance of this sum was determined both by 1000 randomly selected gene sets (the Q1 hypothesis) and 1000 random permutations of the profile labels in the tumor data set (the Q2 hypothesis). The sum of t-scores from the actual data sets were expressed as s.d. from the mean of either the random gene permutation results or the random label permutation results, with two-sided significance P-values determined assuming normal distributions of the permutation results. The higher of the Q1 and Q2 P-values determined enrichment (with both Q1 and Q2 required to move in the same direction).
Abbreviations ER, estrogen receptor alpha; PR, progesterone receptor; mTOR, mammalian target of rapamycin.
